Interactions between nanoparticles and lymphatic systems: Mechanisms and applications in drug delivery

Tang, Yisi; Liu, Bao; Zhang, Yuting; Liu, Yuling; Huang, Yongzhuo; Fan, Wufa

doi:10.1016/j.addr.2024.115304

Cited by 4 publications

(1 citation statement)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particles in the range of 20-100 nm are ideal because they are small enough to enter the lymphatic capillaries, yet large enough to avoid rapid clearance by renal filtration. NPs sized 20-100 nm are optimally designed for lymph node targeting, as their dimensions allow them to enter the lymphatic system through interstitial spaces and travel efficiently to lymph nodes [48,53]. The NPs' ability to target lymph nodes and facilitate DC maturation and antigen presentation is illustrated by the development of a manganese-based nanodriver.…”

Section: How Particle Size and Positive Charge Drive The Immune Respo...mentioning

confidence: 99%

Emerging Cationic Nanovaccines

Carmona-Ribeiro,

Pérez-Betancourt

2024

Preprint

View full text Add to dashboard Cite

Nanovaccines are able to deliver antigen(s) and immunomodulator(s) directly to antigen-presenting cells (APCs) of the lymphatic system. Positive charges improve their uptake by APCs and often drive a Th-1 biased immune response so necessary against infectious diseases caused by intracellular pathogens and cancers. However, cationic compounds often display a dose-dependent toxicity so that systematic evaluation of cytotoxicity against cells in culture is required. After the rapid evolution of nanovaccines against SARS-Covid 2, mRNA vaccines gained much strength and have been designed against several infectious diseases, often relying on cationic components for mRNA protection. Once established the limiting concentration for the cationic compound, cationic nanovaccines perform well eliciting the desired Th-1 improved immune response in most cases. Other valuable approach found in the literature has been the construction of biocompatible nanoparticles (NPs) carrying cationic lipids, polymers or surfactants so that minimization of the concentration for the cationic component led to absence of toxicity. Against cancer, recent constructions of nanovaccines in situ after cancer cell disruption in the presence of adjuvants led to systemic presentation of multiple tumoral antigens yielding, in many instances, prevention of metastasis appearance and conversion of tumors non treatable by immunotherapy into treatable ones.

show abstract

Section: How Particle Size and Positive Charge Drive The Immune Respo...mentioning

confidence: 99%